All
Linvoseltamab BLA Resubmission Accepted by FDA for Review
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.
Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume
Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death by 46%, per ARANOTE data.
Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.
An Expert Explains Updated Data For Patients With GU Cancers
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.
Elevated PSA Link to Higher Recurrence Risk in Intermediate-Risk Prostate Cancer
Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.
Facing Cancer Together: Jim and Melanie’s Patient-Caregiver Story
Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's sarcoma diagnosis.
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma.
Talzenna Plus Xtandi May Improve Survival in mCRPC
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.
Phase 2 Trial of Firi-Cel CAR T-Cell Therapy Discontinued in Lymphoma
The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued.
GI Bleeding Significantly Impacts GIST Treatment Outcomes
The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.
Moving Slower and Slower After Myelodysplastic Syndrome
I have been frustrated lately by my increasing slowness following an blood cancer diagnosis, which has become noticeable to others.
Empowering Patients and Advocating For Yourself After Cervical Cancer
Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.
FDA Approves Adcetris With Revlimid and Rituxan For R/R LBCL
The FDA has approved Adcetris plus Revlimid and Rituxan in adults with relapsed or refractory large B-cell lymphoma.
An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.
Test May Predict Likelihood of Bladder Cancer Upstaging
The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.
Breaking Down The Importance of Targeted Therapies in Colorectal Cancer Care
Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.
Unexpected Support in Tough Times With Multiple Myeloma
Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.
Explaining KRAS Mutations For Patients With Colorectal Cancer
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Personalized Kidney Cancer Vaccine May Help Prevent Future Relapse
In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.
FDA Approval of Calquence Combo Brings Optimism in MCL
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.
The Importance of Utilizing Support Networks Following a Cancer Diagnosis
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine dehydrogenase deficiency.
The Effects of Scanxiety on ‘Normal’ Life
As a cancer survivor, I face added stress with an upcoming black belt test and "scanxiety" before my annual CT scan and oncology appointment.
An Expert Breaks Down What DPD Is and Labeling Updates From The FDA
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.
Lonsurf Shows Survival Benefit Over Placebo in Stage 4 Colorectal Cancer
In patients with residual disease after curative resection of colorectal cancer, Lonsurf showed a numerical improvement in DFS, though not significant.
Pelareorep With Chemo and Tecentriq Shows Acceptable Safety in Metastatic PDAC
Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.
From Patient 3737 to Advocate: The Life-Changing Power of Clinical Trials
Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of cholangiocarcinoma.
Reoperations May Offer Survival Benefit in Recurrent Glioblastoma
When deciding if reoperation is an option in recurrent glioblastoma, factors like tumor location, therapy history and patient health should be considered.
Braftovi Plus Erbitux With mFOLFOX6 May Improve Responses in BRAF V600E+ mCRC
Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.
